Sarepta Therapeutic (SRPT) Has 100% Upside, 50% Downside - Deutsche Bank
Tweet Send to a Friend
Deutsche Bank maintained a Hold rating on Sarepta Therapeutic (NASDAQ: SRPT) with a price target of $24. Yesterday Sarepta said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
